Correspondence to Editorial on "Multiomics Profiling of Buffy Coat and Plasma Unveils Etiology-specific Signatures in Hepatocellular Carcinoma"

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2024 May 20

PMID 38768961

Authors

Su Bin Lim

Hyo Jung Cho

Affiliations

Soon will be listed here.

References

Zheng Q, Sun Q, Yao H, Shi R, Wang C, Ma Z . Single-cell landscape identifies the immunophenotypes and microenvironments of HBV-positive and HBV-negative liver cancer. Hepatol Commun. 2024; 8(2). PMC: 10805423. DOI: 10.1097/HC9.0000000000000364. View

Lim S, Tan S, Lim W, Lim C . An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer. Nat Commun. 2017; 8(1):1734. PMC: 5700969. DOI: 10.1038/s41467-017-01430-6. View

Ahn J, Yang J . Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on "Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma". Clin Mol Hepatol. 2024; 30(4):689-691. PMC: 11540397. DOI: 10.3350/cmh.2024.0348. View

Diniz M, Schurich A, Chinnakannan S, Duriez M, Stegmann K, Davies J . NK cells limit therapeutic vaccine-induced CD8T cell immunity in a PD-L1-dependent manner. Sci Transl Med. 2022; 14(640):eabi4670. DOI: 10.1126/scitranslmed.abi4670. View

Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, Riether C . The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022; 41(1):12. PMC: 8734249. DOI: 10.1186/s13046-021-02215-y. View

Lee S, Jang H . Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology. Clin Mol Hepatol. 2022; 28(4):754-772. PMC: 9597228. DOI: 10.3350/cmh.2021.0394. View

Oh S, Baek Y, Jung S, Yoon S, Kang B, Han S . Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression. Clin Mol Hepatol. 2024; 30(2):247-262. PMC: 11016492. DOI: 10.3350/cmh.2023.0449. View

Dong M, Thuy L, Hoang D, Hai H, Huu Hoang T, Sato-Matsubara M . Soluble Immune Checkpoint Protein CD27 Is a Novel Prognostic Biomarker of Hepatocellular Carcinoma Development in Hepatitis C Virus-Sustained Virological Response Patients. Am J Pathol. 2022; 192(10):1379-1396. DOI: 10.1016/j.ajpath.2022.07.003. View

Hong J, Eun J, Baek G, Cheong J, Park S, Kim S . Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma. Clin Mol Hepatol. 2024; 30(3):360-374. PMC: 11261225. DOI: 10.3350/cmh.2024.0042. View

10.

Kui X, Wang Y, Zhang C, Li H, Li Q, Ke Y . Prognostic value of SH3PXD2B (Tks4) in human hepatocellular carcinoma: a combined multi-omics and experimental study. BMC Med Genomics. 2021; 14(1):115. PMC: 8080318. DOI: 10.1186/s12920-021-00963-6. View

11.

Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo B . Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2022; 41(7):1434-1443. PMC: 9995104. DOI: 10.1200/JCO.22.00620. View

12.

Finn R, Ryoo B, Merle P, Kudo M, Bouattour M, Lim H . Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2019; 38(3):193-202. DOI: 10.1200/JCO.19.01307. View

13.

Sohn W, Paik Y . Correspondence on Editorial regarding "Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease". Clin Mol Hepatol. 2022; 29(1):182-184. PMC: 9845662. DOI: 10.3350/cmh.2022.0411. View

14.

Sogbe M, Bilbao I, Marchese F, Zazpe J, De Vito A, Pozuelo M . Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment. Clin Mol Hepatol. 2024; 30(2):177-190. PMC: 11016491. DOI: 10.3350/cmh.2023.0426. View